An administrative judge ruled Illumina’s $8 billion acquisition of cancer-testing company Grail didn’t violate antitrust law, Illumina said on Thursday.
A Federal Trade Commission lawsuit threatened to unwind Illumina’s acquisition of Grail, a blood testing company that screens for cancers at an early stage.
“As we’ve stated from the outset, this transaction is procompetitive, will advance innovation, lower healthcare costs and save lives,” Illumina general counsel Charles Dadswell said in a statement.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 149,500+ biopharma pros reading Endpoints daily — and it’s free.